Unique ID issued by UMIN | UMIN000044031 |
---|---|
Receipt number | R000050279 |
Scientific Title | Evaluation of the impact of CAD EYE on the quality of colonoscopy and the learning curve of gastroenterology fellows |
Date of disclosure of the study information | 2021/04/26 |
Last modified on | 2023/04/27 14:52:31 |
Evaluation of the impact of CAD EYE on the quality of colonoscopy and the learning curve of gastroenterology fellows
cad eye b study
Evaluation of the impact of CAD EYE on the quality of colonoscopy and the learning curve of gastroenterology fellows
cad eye b study
Japan |
Patients who were referred and scheduled for total colonoscopy
Gastroenterology |
Others
NO
To conduct a randomized clinical trial of endoscopic observation using CAD EYE and normal endoscopic observation (WLI) to compare the adenoma detection and polyp miss rates.
Efficacy
Adenoma Detection Rate
Interventional
Cross-over
Randomized
Individual
Single blind -participants are blinded
Active
2
Prevention
Device,equipment |
Group A: Colonoscopy observation with CAD EYE
Group B: Colonoscopy observation with WLI
18 | years-old | <= |
79 | years-old | >= |
Male and Female
1 patients between 18 and 79 years of age (at the time of signing the consent form) undergoing lower gastrointestinal endoscopy.
2 patients who understand the contents of the consent document and can sign the consent form of their own free will (in the case of minors, their guardians).
3 patients who are required to undergo lower gastrointestinal endoscopy (patients who meet any of the following conditions)
patients with positive fecal occult blood
patients who have been previously diagnosed or treated for colorectal adenoma or colorectal cancer (not applicable for those who have undergone colorectal resection)
those with digestive symptoms such as abdominal pain, diarrhea, constipation, etc.
those who need to be screened for gastrointestinal cancer.
those who have a family history of colorectal cancer or colorectal adenoma.
those who have a family history of colorectal cancer or colorectal adenoma
other patients who are judged to need lower gastrointestinal endoscopy by the physician in charge
patients who have undergone bowel resection.
patients with a history of inflammatory bowel disease.
patients with a history of familial adenomatous polyposis
patients with a history of hereditary non-polyposis colorectal cancer
patients with a known history of severe intestinal adhesions
patients who are judged by their physician to be unable to participate in the study
240
1st name | Daisuke |
Middle name | |
Last name | Yamaguchi |
Ureshino Medical Center
Gastroenterology
8430393
Shimojyukukou 4279-3, Ureshino city
0954431120
daisukehawks@gmail.com
1st name | Daisuke |
Middle name | |
Last name | Yamaguchi |
Ureshino Medical Center
Gastroenterology
8430393
Shimojyukukou 4279-3, Ureshino city
0954431120
daisukehawks@gmail.com
Ureshino Medical Center
None
Other
Institutional Review Board of Ureshino Medical Center
Shimojyukukou 4279-3, Ureshino city
0954431120
honjo.yoko.vd@mail.hosp.go.jp
NO
2021 | Year | 04 | Month | 26 | Day |
https://onlinelibrary.wiley.com/doi/10.1111/den.14573
Published
https://onlinelibrary.wiley.com/doi/10.1111/den.14573
231
We analyzed data for 231 patients (Group A, n=113; Group B, n=118). The ADR was not significantly different between the two groups. Group A had a significantly lower AMR (25.6% vs. 38.6%, p=0.033) and number of missed adenomas per patient (0.5 vs. 0.9, p=0.004) than Group B.
2023 | Year | 04 | Month | 27 | Day |
The patients in this multicenter randomized controlled trial were divided into Group A (observation using CAD EYE) and Group B (standard observation). Six trainees performed colonoscopies using a back-to-back method in pairs with gastroenterology experts. The primary endpoint was the trainees' adenoma detection rate (ADR), and the secondary endpoints were the trainees' adenoma miss rate (AMR) and Assessment of Competency in Endoscopy (ACE) tool scores. Each trainee's learning curve was evaluated using a cumulative sum (CUSUM) control chart.
The study involved adults aged >20 years who were scheduled for outpatient colonoscopy from May 2021 to March 2022. The colonoscopy examinations were performed either because of a positive fecal immunochemical test or for surveillance after colonic polypectomy. We excluded patients with ileus, suspected bowel obstruction, or toxic megacolon; prior abdominal or pelvic surgery; inflammatory bowel disease; advanced malignancy; severe liver damage (Child-Pugh gradeC); dementia or other cognitive disorders; hypersensitivity to bowel preparation drugs for colonoscopy; and pregnancy or lactation.
No perioperative severe adverse events were observed in this study.
We analyzed data for 231 patients (Group A, n=113; Group B, n=118). The ADR was not significantly different between the two groups. Group A had a significantly lower AMR (25.6% vs. 38.6%, p=0.033) and number of missed adenomas per patient (0.5 vs. 0.9, p=0.004) than Group B. Group A also had significantly higher ACE tool scores for pathology identification (2.26 vs. 2.07, p=0.030) and interpretation and identification of pathology location (2.18 vs. 2.00, p=0.038). For the CUSUM learning curve, Group A showed a trend toward a lower number of cases of missed multiple adenomas by the six trainees.
Completed
2021 | Year | 04 | Month | 26 | Day |
2021 | Year | 03 | Month | 25 | Day |
2021 | Year | 05 | Month | 10 | Day |
2022 | Year | 03 | Month | 31 | Day |
2021 | Year | 04 | Month | 25 | Day |
2023 | Year | 04 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050279